3.8 Review

Genetics of Diabetic Nephropathy: Are There Clues to the Understanding of Common Kidney Diseases?

Journal

NEPHRON CLINICAL PRACTICE
Volume 112, Issue 4, Pages C213-C220

Publisher

KARGER
DOI: 10.1159/000224787

Keywords

Genetics; Susceptibility gene; Polymorphism; Diabetic nephropathy; Kidney disease

Ask authors/readers for more resources

Diabetic nephropathy is the most common cause of end-stage renal disease in the Western world. There is evidence for a genetic susceptibility to diabetic kidney disease, but despite intensive research efforts it has proved difficult to identify the causative genes. Improvements in genotyping technologies have made genome-wide association studies (GWAS), employing hundreds of thousands of single nucleotide polymorphisms, affordable. Recently, such scans have advanced understanding of the genetics of common complex diseases, finding more than 100 novel susceptibility variants for diverse disorders including type 1 and 2 diabetes, coronary heart disease, Crohn's disease and rheumatoid arthritis. In this review, type 2 diabetes is highlighted to illustrate how genome-wide association studies have been used to study the genetics of complex multifactorial conditions; in addition, diabetic nephropathy will be used to demonstrate how similar scans could be employed to detect genetic factors predisposing to kidney disease. The identification of such variants would permit early identification of at-risk patients, enabling targeting of therapy and a move towards primary prevention. In addition, these powerful research methodologies may identify genes that were not previously known to predispose to nephropathy, thereby enhancing our understanding of the pathophysiology of renal disorders and potentially leading to novel therapeutic approaches. Copyright (C) 2009 S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Health Care Sciences & Services

Quality of life in advanced renal disease managed either by haemodialysis or conservative care in older patients

Clare McKeaveney, Miles Witham, Abrar O. Alamrani, Alexander Peter Maxwell, Robert Mullan, Helen Noble, Joanne Shields, Joanne Reid

Summary: The objective of this study was to report on quality of life and other functional outcomes in patients with advanced chronic kidney disease. The study found that patients receiving hemodialysis had significantly better scores on the Symptoms/Problems List subscale of the KDQoL-36 questionnaire compared to those under conservative management. However, there was no significant difference in the Burden of Kidney Disease subscale scores between the two groups. These findings suggest the use of quality of life assessment tools for clinical prognostication and appropriate management of advanced CKD patients.

BMJ SUPPORTIVE & PALLIATIVE CARE (2023)

Article Endocrinology & Metabolism

Genome-wide meta-analysis and omics integration identifies novel genes associated with diabetic kidney disease

Niina Sandholm, Joanne B. Cole, Viji Nair, Xin Sheng, Hongbo Liu, Emma Ahlqvist, Natalie van Zuydam, Emma H. Dahlstrom, Damian Fermin, Laura J. Smyth, Rany M. Salem, Carol Forsblom, Erkka Valo, Valma Harjutsalo, Eoin P. Brennan, Gareth J. McKay, Darrell Andrews, Ross Doyle, Helen C. Looker, Robert G. Nelson, Colin Palmer, Amy Jayne McKnight, Catherine Godson, Alexander P. Maxwell, Leif Groop, Mark I. McCarthy, Matthias Kretzler, Katalin Susztak, Joel N. Hirschhorn, Jose C. Florez, Per-Henrik Groop

Summary: By performing meta-analysis of previous genome-wide association studies (GWAS) on diabetic kidney disease (DKD) and integrating the results with renal transcriptomics datasets, novel genetic factors and genes contributing to DKD have been identified.

DIABETOLOGIA (2022)

Article Multidisciplinary Sciences

Exploring the lived experience of renal cachexia for individuals with end-stage renal disease and the interrelated experience of their carers: Study protocol

Carolyn Blair, Joanne Shields, Robert Mullan, William Johnston, Andrew Davenport, Denis Fouque, Kamyar Kalantar-Zadeh, Peter Maxwell, Clare McKeaveney, Helen Noble, Sam Porter, David Seres, Adrian Slee, Ian Swaine, Miles Witham, Joanne Reid

Summary: This study aims to explore the lived experience of individuals with renal cachexia and their carers, in order to inform guidelines and future renal service planning.

PLOS ONE (2022)

Article Medicine, General & Internal

Empagliflozin in Patients with Chronic Kidney Disease

William G. Herrington, Natalie Staplin, Christoph Wanner, Jennifer B. Green, Sibylle J. Hauske, Jonathan R. Emberson, David Preiss, Parminder Judge, Kaitlin J. Mayne, Sarah Y. A. Ng, Emily Sammons, Doreen Zhu, Michael Hill, Will Stevens, Karl Wallendszus, Susanne Brenner, Alfred K. Cheung, Zhi-Hong Liu, Jing Li, Lai Seong Hooi, Wen Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Cherney, Aldo P. Maggioni, Roberto Pontremoli, Rajat Deo, Shinya Goto, Xavier Rossello, Katherine R. Tuttle, Dominik Steubl, Michaela Petrini, Dan Massey, Jens Eilbracht, Martina Brueckmann, Martin J. Landray, Colin Baigent, Richard Haynes

Summary: Empagliflozin therapy reduces the risk of disease progression or cardiovascular death in patients with chronic kidney disease.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Article Multidisciplinary Sciences

Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: A cost-effectiveness analysis

Luke E. Barry, Grainne E. Crealey, Paul Cockwell, Stephen J. Elliman, Matthew D. Griffin, Alexander P. Maxwell, Timothy O'Brien, Norberto Perico, Ciaran O'Neill

Summary: This study simulated the cost-effectiveness of Mesenchymal Stromal Cell therapy compared to other treatments in patients with Diabetic Kidney Disease. The results showed that Mesenchymal Stromal Cell therapy was more cost-effective compared to other treatments. However, sodium/glucose co-transporter 2 inhibitors had the highest cost-effectiveness among all the treatments.

PLOS ONE (2022)

Article Multidisciplinary Sciences

Epigenome-wide meta-analysis identifies DNA methylation biomarkers associated with diabetic kidney disease

Laura J. Smyth, Emma H. Dahlstrom, Anna Syreeni, Katie Kerr, Jill Kilner, Ross Doyle, Eoin Brennan, Viji Nair, Damian Fermin, Robert G. Nelson, Helen C. Looker, Christopher Wooster, Darrell Andrews, Kerry Anderson, Gareth J. McKay, Joanne B. Cole, Rany M. Salem, Peter J. Conlon, Matthias Kretzler, Joel N. Hirschhorn, Denise Sadlier, Catherine Godson, Jose C. Florez, Carol Forsblom, Alexander P. Maxwell, Per-Henrik Groop, Niina Sandholm, Amy Jayne McKnight

Summary: This study investigated DNA methylation in 1304 individuals with type 1 diabetes and identified differentially methylated CpG sites associated with diabetic kidney disease. The methylation at 21 of these sites was found to predict the development of kidney failure.

NATURE COMMUNICATIONS (2022)

Article Urology & Nephrology

Longitudinal Epigenome-Wide Analysis of Kidney Transplant Recipients Pretransplant and Posttransplant

Laura J. Smyth, Katie R. Kerr, Jill Kilner, Aine E. McGill, Alexander P. Maxwell, Amy Jayne McKnight

Summary: This study analyzed the DNA methylation of kidney transplant recipients and identified markers associated with the risk of transplant complications. The findings provide an important reference for future epigenetic studies on posttransplant complications.

KIDNEY INTERNATIONAL REPORTS (2023)

Article Multidisciplinary Sciences

A genome-wide association study identifies a possible role for cannabinoid signalling in the pathogenesis of diabetic kidney disease

Wael Osman, Mira Mousa, Mohammed Albreiki, Zahrah Baalfaqih, Hinda Daggag, Claire Hill, Amy Jayne McKnight, Alexander P. Maxwell, Habiba Al Safar

Summary: Diabetic kidney disease (DKD), or diabetic nephropathy, is a major cause of renal impairment and end-stage renal disease. This study conducted a genome-wide association study to investigate genetic factors associated with the development and progression of DKD in the Emirati population. The CNR2 gene was found to be significantly associated with the development of DKD in individuals with type 2 diabetes mellitus (T2DM).

SCIENTIFIC REPORTS (2023)

Article Genetics & Heredity

Differential Methylation of Telomere-Related Genes Is Associated with Kidney Disease in Individuals with Type 1 Diabetes

Claire Hill, Seamus M. Duffy, Laura Kettyle, Liane McGlynn, Niina M. Sandholm, Rany Salem, Alex J. Thompson, Elizabeth Swan, Jill Kilner, Peter G. Rossing, Paul Shiels, Maria Lajer, Per-Henrik Groop, Alexander Peter Maxwell, Amy Jayne McKnight, GENIE Consortium

Summary: Diabetic kidney disease (DKD) is a major global health problem characterized by accelerated aging. This study explored features affecting telomere biology and methylation dysregulation in DKD using multi-omics approaches, which may provide useful biomarkers or therapeutic targets.

GENES (2023)

Review Genetics & Heredity

Harnessing Genomic Analysis to Explore the Role of Telomeres in the Pathogenesis and Progression of Diabetic Kidney Disease

Claire Hill, Seamus Duffy, Tiernan Coulter, Alexander Peter Maxwell, Amy Jayne McKnight

Summary: The global prevalence of diabetes is increasing and research is needed to find new ways to manage it. Diabetes can lead to kidney disease, which is a burden to patients and healthcare services. This review highlights studies on genomic and functional prediction tools that have identified genes and pathways associated with diabetic kidney disease, particularly focusing on the regulation of telomere length. The potential to use therapeutics that modulate telomere length for the treatment of diabetic kidney disease is discussed in the review.

GENES (2023)

Article Urology & Nephrology

Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM)

Norberto Perico, Giuseppe Remuzzi, Matthew D. Griffin, Paul Cockwell, Alexander P. Maxwell, Federica Casiraghi, Nadia Rubis, Tobia Peracchi, Alessandro Villa, Marta Todeschini, Fabiola Carrara, Bernadette A. Magee, Piero L. Ruggenenti, Stefano Rota, Laura Cappelletti, Veronica Mcinerney, Tomas P. Griffin, Md Nahidul Islam, Martino Introna, Olga Pedrini, Josee Golay, Andrew A. Finnerty, Jon Smythe, Willem E. Fibbe, Stephen J. Elliman, Timothy O'Brien, NEPHSTROM Trial Consortium

Summary: The NEPHSTROM study evaluates the safety, tolerability, and preliminary efficacy of ORBCEL-M cell therapy in adults with type 2 diabetes and progressive diabetic kidney disease. The results show that ORBCEL-M cell therapy is safe and well-tolerated in the lowest dose cohort, and significantly reduces the decline rate of eGFR over 18 months.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Article Urology & Nephrology

Early clinical and economic outcomes of expanded criteria living kidney donors in the United States

Nga T. Q. Nguyen, Aisling E. E. Courtney, Hoa Q. Q. Nguyen, Michael Quinn, Alexander P. P. Maxwell, Ciaran O'Neill

Summary: This study aimed to assign expanded criteria and non-expanded criteria donation status and examine early clinical and economic outcomes among expanded criteria and non-expanded criteria living kidney donor (LKD) hospitalizations in the US.

JOURNAL OF NEPHROLOGY (2023)

Review Urology & Nephrology

Proteomic analysis investigating kidney transplantation outcomes- a scoping review

Anna Rainey, Gareth J. Mckay, Jane English, Ammarin Thakkinstian, Alexander Peter Maxwell, Michael Corr

Summary: Kidney transplantation is the optimal treatment for most patients with end-stage kidney disease, but rejection and graft failure remain common. The development of non-invasive biomarkers to monitor graft function and predict transplant outcomes is still needed. Proteomic investigation has identified potential biomarkers, but their clinical translation and adoption are limited and require further evaluation in larger trials.

BMC NEPHROLOGY (2023)

Article Health Care Sciences & Services

Developing an Evidence and Theory Based Multimodal Integrative Intervention for the Management of Renal Cachexia: A Theory of Change

Carolyn Blair, Adrian Slee, Andrew Davenport, Denis Fouque, William Johnston, Kamyar Kalantar-Zadeh, Peter Maxwell, Clare McKeaveney, Robert Mullan, Helen Noble, Sam Porter, David Seres, Joanne Shields, Ian Swaine, Miles Witham, Joanne Reid

Summary: This study aimed to develop a theoretical framework for a multimodal intervention for patients with renal cachexia. The researchers used a Theory of Change approach to guide the development of the framework and provide evidence for the effectiveness of the intervention.

HEALTHCARE (2022)

Article Health Care Sciences & Services

Dialysis, Distress, and Difficult Conversations: Living with a Kidney Transplant

Clare McKeaveney, Helen Noble, Aisling E. Courtney, Sian Griffin, Paul Gill, William Johnston, Alexander P. Maxwell, Francesca Teasdale, Joanne Reid

Summary: This study aims to gain an in-depth understanding of the lived experiences of kidney transplant recipients. The results revealed that the participants continue to manage ongoing fears of dialysis, distress, and the impact of COVID-19, as well as dealing with difficult conversations. Renal healthcare professionals need to recognize the holistic and multidomain experiences of kidney patients to provide responsive psychosocial care.

HEALTHCARE (2022)

No Data Available